TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28234053
Drug: BI 671800
Normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 671800 200 mg twice daily with fluticasone propionate
Study: 28234053
Drug: BI 671800
Normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 671800 400 mg A.M. with fluticasone propionate
Study: 24010986
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received a single buccal injection and a single palatal injection before extraction
Study: 7768075
Drug: Halofantrine 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine 4.5 gm 7‐day loading dose regimen
Study: 2138683
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins plus 75 mg diclofenac
Study: 2138683
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg diclofenac alone
Study: 7459427
Drug: U.K. sales
Approvals — FDA: no, EMA: no, PMDA: no
Description: U.K. sales tablet
Study: 7459427
Drug: Two tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablet formulations
Study: 6355931
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution
Study: 28041599
Drug: 200mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg of fermented soy containing 10mg of equol and 25mg of resveratrol (1 tablet/day)
Study: 23963546
Drug: Valsartan/amlodipine 80/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/amlodipine 80/5 mg
Study: 7965282
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 30 mg
Study: 15753494
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg.kg(‐1), remifentanil 2 mug.kg(‐1), propofol 2 mg.kg(‐1) (Group P)
Study: 15753494
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg.kg(‐1), remifentanil 2 mug.kg(‐1), thiopental 5 mg.kg(‐1) (Group T)
Study: 9834264
Drug: L‐NMMA (NG‐monomethyl‐L‐arginine),
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (NG‐monomethyl‐L‐arginine), a specific NO synthase blocker
Study: 31751782
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (100,000 IU monthly)
Study: 29199184
Drug: Regular scoliosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular scoliosis specific exercises (SSE) as treatment as usual.
Study: 17472181
Drug: Other treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatment protocols (not specified)
Study: 15853959
Drug: Levocetirizine 5
Normalized name: Levocetirizine 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 5 mg once-daily
Study: 8562975
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 320 mg/day
Study: 8562975
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate treatment
Study: 2235226
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg per day for 7 days, followed by hydrocortisone 8 mg/kg per day for 10 days)
Study: 760755
Drug: Intravenous heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heroin (2.5 mg and 5 mg) in non-dependent subjects
Study: 24737258
Drug: Ulinastatin (200,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (200,000 IU) administered intravenously 12 hourly for 5 days
Study: 24737258
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously 12 hourly for 5 days
Study: 17955229
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg tizanidine (in male smokers)
Study: 31068225
Drug: Partner-assisted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partner-assisted cognitive behavioural therapy for insomnia (PA-CBTI)
Study: 31068225
Drug: Traditional individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional individual cognitive behavioural therapy for insomnia (i-CBTI)
Study: 24637282
Drug: 4% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% hypertonic saline solution mouthwash
Study: 3202338
Drug: Alcuronium (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium (0.03 mg.kg‐1)
Study: 3202338
Drug: Atracurium (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.04 mg.kg‐1)
Study: 3202338
Drug: Pancuronium (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.01 mg.kg‐1)
Study: 30851066
Drug: Telmisartan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 1.5 mg/kg PO q12h for 14 days, followed by 2 mg telmisartan/kg PO q24h
Study: 16963035
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg/d for 12 months
Study: 14767410
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g/day divided into 4 doses of 5 g each)
Study: 10397206
Drug: Intravenous fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous fluconazole (400 mg per day)
Study: 1518122
Drug: Panipenem/betamipron (PAPM/BP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panipenem/betamipron (PAPM/BP) 10 mg/10 mg/kg
Study: 1518122
Drug: Panipenem/betamipron (PAPM/BP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panipenem/betamipron (PAPM/BP) 20 mg/20 mg/kg
Study: 6412270
Drug: Amitriptyline (AT)
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline (AT) during treatment
Study: 31494058
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (n=61) - received high-carotenoid FVs
Study: 30921297
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment without serious adverse events (SAEs)
Study: 30921297
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with serious adverse events (SAEs)
Study: 20717045
Drug: Aspirin enteric-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin enteric-coated 81 mg once daily
Study: 18930599
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone replacement therapy (Genotropin; Pfizer) for 6 months
Study: 2465747
Drug: Regimen II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen II: Intramuscular bleomycetin (10 mg on days 1-3), intravenous 5-fluorouracil (400 mg/m2 on days 1-3), intravenous cisplatin (100-150 mg/m2 on day 4)
Study: 2656603
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements
Study: 30106529
Drug: Two-step oral
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step oral hygiene sequence: 0.454% stannous fluoride dentifrice followed by 3.0% hydrogen peroxide whitening gel
Study: 23216100
Drug: Topical epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical epidural of preservative‐free morphine and dexmedetomidine administered via gel foam
Study: 23216100
Drug: Both forms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both forms of analgesia (topical epidural and hydromorphone)
Study: 12666468
Drug: Brief Strategic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Strategic Family Therapy (BSFT)
Study: 10851665
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) therapy
Study: 1527539
Drug: Epanutin capsules
Normalized name: phenytoin sodium Oral Capsule [Epanutin]
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epanutin capsules
Study: 1527539
Drug: Generic 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic 100 mg tablets
Study: 30304141
Drug: Mecobalamin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecobalamin (500 µg three times a day)
Study: 27382813
Drug: 0.1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg.kg‐1 oxycodone intravenously 10 min prior to the operation for 2 min
Study: 16251309
Drug: Tigecycline 100
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline 100 mg/day
Study: 11867387
Drug: Urapidil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (25 mg administered IV after 10 min of shivering)
Study: 8531933
Drug: Terbinafine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine treatment course 1
Study: 8531933
Drug: Terbinafine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine treatment course 3
Study: 7358867
Drug: Oral Nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nefopam
Study: 21925126
Drug: BI 207127
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 207127 400 mg 3 times daily plus 120 mg BI 201335 once daily and 1000 to 1200 mg/day ribavirin
Study: 7351677
Drug: Supplemental albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental albumin infusion (31 gm during operation followed by 150 gm/day for 5 days)
Study: 19579605
Drug: 5-day terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day terlipressin treatment (Group A)
Study: 19579605
Drug: 10-day terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day terlipressin treatment (Group B)
Study: 17805339
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO), administered for > or = 24 days
Study: 17805339
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered for > or = 24 days
Study: 8574715
Drug: Intravenous cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefuroxime
Study: 2236712
Drug: Bupivacaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 15 mg with epinephrine 1:200,000 in 2 ml (0.75%)
Study: 2236712
Drug: Bupivacaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 15 mg with epinephrine 1:200,000 in 3 ml (0.5%)
Study: 2236712
Drug: Bupivacaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 15 mg with epinephrine 1:200,000 in 6 ml (0.25%)
Study: 2236712
Drug: Bupivacaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 15 mg with epinephrine 1:200,000 in 9 ml (0.166%)
Study: 2236712
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine 7.5 mg in 3 ml (0.25%)
Study: 2236712
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine 15 mg in 3 ml (0.5%)
Study: 2236712
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine 22.5 mg in 3 ml (0.75%)
Study: 9816659
Drug: Repair with
Normalized name: AVOBENZONE 30 mg in 1 g / OCTINOXATE 75 mg in 1 g / OCTISALATE 50 mg in 1 g TOPICAL CREAM [Exuviance Age Reverse Day Repair with Sunscreen Broad Spectrum SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repair with PDS II-cord augmentation (G1)
Study: 9816659
Drug: Late BTB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late BTB ligament replacement with PDS II-cord augmentation (G4)
Study: 7912875
Drug: Melperon (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melperon (15-30 mg)
Study: 2731086
Drug: Flunarizine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (15 mg daily)
Study: 1140623
Drug: Intravenous metiamide
Normalized name: metrizamide
DrugBank: Metrizamide (DB01578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metiamide
Study: 17885347
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy treatment
Study: 26080850
Drug: Glutamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (20 g/d), EPA (3.3 g/d), branched-chain amino acids (8 g/d)
Study: 22641239
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg every 6 months for 36 months
Study: 21158148
Drug: HBO pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO pretreatment twice (Group A)
Study: 15858959
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii (250 mg daily for 5 days)
Study: 20098455
Drug: G-CSF mobilization
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF mobilization
Study: 1879246
Drug: Surfactant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant treatment (SF‐RI 1)
Study: 18390968
Drug: AZD6244 (50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6244 (50% MTD, 100 mg bid)
Study: 18390968
Drug: AZD6244 (MTD,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6244 (MTD, 200 mg bid)
Study: 31501069
Drug: Cream-type adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream-type adhesive
Study: 27756441
Drug: Control (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isotonic sodium chloride solution)
Study: 17692153
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg daily for 6 weeks, increased to 20 mg after 6 weeks, then to 40 mg after 12 weeks
Study: 16254818
Drug: Bonistein 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bonistein 60 mg once daily for 14 days
Study: 16254818
Drug: Bonistein 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bonistein 120 mg once daily for 14 days
Study: 16254818
Drug: Bonistein (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bonistein (all doses)
Study: 12121609
Drug: One-stage surgery
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage surgery with two-piece implants (group A)
Study: 12121609
Drug: Two-stage surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage surgery with two-piece implants (group B, control)
Study: 12121609
Drug: One-stage surgery
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage surgery with one-piece implants (group C)
Study: 11966737
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) replacement therapy
Study: 1363657
Drug: Zolpidem 10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10-20 mg
Study: 17485161
Drug: BCG 27
Normalized name: BCG 27 mg intravesical powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 27 mg
Study: 17485161
Drug: BCG 13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 13.5 mg
Study: 17485161
Drug: MMC 30
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC 30 mg
Study: 15517239
Drug: PSV cutpoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSV cutpoint of 250 cm/s for consideration of chronic transfusion treatment
Study: 7614164
Drug: Topical podophyllum
Normalized name: Podophyllum
DrugBank: Podophyllin (DB09094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical podophyllum resin 25% solution
Study: 6571946
Drug: Intermediate-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose methotrexate plus intrathecal methotrexate
Study: 22369224
Drug: Cognitive-behavioral treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatments for alcohol-dependent women
Study: 19172031
Drug: Topical finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical finasteride (1% gel)
Study: 19172031
Drug: Oral finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral finasteride (1 mg tablet)
Study: 19172031
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (topical and oral finasteride)
Study: 17426085
Drug: Diane(35) Diario
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane(35) Diario (35 microg of ethinyl‐estradiol plus 2 mg of cyproterone acetate)
Study: 28770322
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg twice daily)
Study: 12006162
Drug: Ginkgo (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo (60 mg TID)
Study: 7637151
Drug: No glucose
Normalized name: No glucose hemofiltration solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: No glucose infusion (control group)
Study: 2617243
Drug: Cold cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold cardioplegic solution allowed to pass through the lungs (n = 27)
Study: 31464945
Drug: Inhalation sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation sedation with acclimatization visit
Study: 31464945
Drug: Inhalation sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation sedation without acclimatization visit
Study: 26057627
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (48 weeks treatment with 1.5 μg/kg Pegylated Interferon alpha and 800-1400 mg Ribavirin)
Study: 26057627
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (36 weeks treatment with 1.5 μg/kg Pegylated Interferon alpha and 800-1400 mg Ribavirin)
Study: 23076431
Drug: N(G)‐nitro‐l‐arginine methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)‐nitro‐l‐arginine methyl ester hydrochloride (L‐NAME, 20 mM)
Study: 23076431
Drug: Eutectic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic mixture of local anaesthetics (EMLA) cream (2.5% lidocaine and 2.5% prilocaine)
Study: 17070146
Drug: Oral ivabradine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ivabradine (5 mg twice daily for 2 weeks then target dose of 7.5 mg twice daily)
Study: 3525829
Drug: Existing general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing general practitioner treatment without the package
Study: 28921624
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose, then 90 mg twice daily)
Study: 27267068
Drug: Bone marrow-derived
Normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow-derived mononuclear cells (BM-MNC) treatment (early, administered 5 to 7 days after AMI)
Study: 27267068
Drug: Bone marrow-derived
Normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow-derived mononuclear cells (BM-MNC) treatment (late, administered 3 to 4 weeks after AMI)
Study: 23583566
Drug: FBC 9/320
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBC 9/320 μg bid
Study: 23583566
Drug: SFC 50/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC 50/250 μg bid
Study: 10589367
Drug: Combination cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination cyclosporine and chloroquine
Study: 1884543
Drug: Single-agent adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent adjuvant chemotherapy
Study: 1884543
Drug: Six-agent, alternating,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-agent, alternating, adjuvant postoperative chemotherapy
Study: 1884543
Drug: Alternating, multiagent,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating, multiagent, adjuvant chemotherapy
Study: 31331699
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg per day for up to 1 year
Study: 31331699
Drug: Methotrexate-vinblastine (vinblastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate-vinblastine (vinblastine 5 mg/m2 per dose and methotrexate 30 mg/m2 per dose, administered weekly for 6 months and then every other week for 6 months)
Study: 29282088
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by surgical resection of primary and metastases
Study: 29282088
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with trastuzumab if Her2+ (4 cycles)
Study: 18541827
Drug: Topiramate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (up to 300 mg/d)
Study: 16340383
Drug: 750 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/day valproate
Study: 16340383
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day topiramate
Study: 2256579
Drug: High Group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Group I allergenic house dust (8.4 micrograms/g)
Study: 27503042
Drug: Bilastine 20
Normalized name: Bilastine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilastine 20 mg
Study: 31906999
Drug: Increased H1-antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased H1-antihistamine dose (twofold)
Study: 30265341
Drug: E-cigs with
Normalized name: E-Z Scrub with Ultradex
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-cigs with 10% of labeled propylene glycol (PG), glycerol (G), and nicotine
Study: 30265341
Drug: Smokers smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smokers smoking 10 non-filter cigarettes spiked with labeled PG, G, and nicotine
Study: 23398595
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment plus radiotherapy